SCHEMBL2952250

SCHEMBL2952250

Cc1ccc(C(=O)O)cc1S

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MYC P01106 1/20 0.47
ESR1 P03372 1/20 0.47
ALOX15 P16050 1/20 0.47
PTPN7 P35236 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TP53 P04637 1/20 0.46
GRM1 Q13255 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 2/20 0.45
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA4 P22748 2/20 0.45
CA6 P23280 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4211367 0.84 TSHR (0.53) TSHRSMN1; SMN2ALDH1A1MYCESR1
SCHEMBL8019701 0.83 CYP2A6 (0.47) SMN1; SMN2ALDH1A1TDP1KMT2APOLB
SCHEMBL21383062 0.81 TSHR (0.55) TSHRSMN1; SMN2ALDH1A1ALOX15TP53
SCHEMBL13495898 0.81 PARP1 (0.48) TSHRSMN1; SMN2ALDH1A1HSD17B10TDP1
SCHEMBL29421064 0.79 CES2 (0.63) TSHRSMN1; SMN2ALDH1A1MYCESR1
SCHEMBL310259 0.79 CES2 (0.63) TSHRSMN1; SMN2ALDH1A1MYCESR1
SCHEMBL13495879 0.78 HDAC6 (0.48) TSHRSMN1; SMN2CA2
SCHEMBL9132393 0.78 TDP1 (0.53) TSHRSMN1; SMN2ALDH1A1ALOX15HSD17B10
SCHEMBL6917591 0.77 CES2 (0.61) TSHRSMN1; SMN2ALDH1A1MYCESR1
SCHEMBL6915822 0.77 CES2 (0.61) TSHRSMN1; SMN2ALDH1A1MYCESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP claimed
CN-104379714-A Malodor reduction compositions PROCTER & GAMBLE 2015-02-25 CN claimed
US-12245446-B2 Semiconductor device having quantum dots, display device, imaging system, and moving body CANON KABUSHIKI KAISHA (JP) 2025-03-04 US disclosed
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-113285024-A Semiconductor device having quantum dots, display device, imaging system, and moving object 佳能株式会社 2021-08-20 CN disclosed
US-20210242416-A1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY CANON KABUSHIKI KAISHA (JP) 2021-08-05 US disclosed
US-20040067990-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C (US) 2004-04-08 US disclosed
US-20040067989-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BARRISH JOEL C (US) 2004-04-08 US disclosed
US-6706717-B2 ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB COMPANY 2004-03-16 US disclosed
EP-1347971-A1 THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES Bristol-Myers Squibb Company (US) 2003-10-01 EP disclosed
CN-1423635-A Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL IND CO LTD (JP) 2003-06-11 CN disclosed
US-20030069238-A1 Thiazolyl inhibitors of Tec family tyrosine kinases BRISTOL-MYERS SQUIBB COMPANY 2003-04-10 US disclosed
WO-2002050071-A1 THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-06-27 WO disclosed
EP-0409729-B1 Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics CIRD GALDERMA (FR) 1994-01-12 EP disclosed
EP-0409729-A1 Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB TSHR 4351/4885SMN1; SMN2 40/4885ALDH1A1 2571/4885
US-20040067990-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK TSHR 2760/4885SMN1; SMN2 4593/4885ALDH1A1 2945/4885
US-20040067989-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK TSHR 2760/4885SMN1; SMN2 4593/4885ALDH1A1 2945/4885
US-20030069238-A1 Thiazolyl inhibitors of Tec family tyrosine kinases TEC, LCK, LTK TSHR 2760/4885SMN1; SMN2 4593/4885ALDH1A1 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.